BiotechTube
Jupiter BioMedical Research

Jupiter BioMedical Research

Miami, United States· Est.
jupiterbiomedicalresearch.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Jupiter Biomedical Research is a preclinical-stage biotech focused on developing novel small molecule therapeutics for oncology and virology. Its lead asset, JBR-102, is being developed as an oral formulation for glioblastoma and other solid and hematologic tumors, while JBR-201 is an antiviral candidate with potential activity against a broad spectrum of viruses. The company appears to be a private, pre-revenue entity with a management team listed on its website but no disclosed clinical data, investors, or partners, indicating an early-stage venture seeking to advance its candidates into clinical development.

OncologyVirology

Technology Platform

Focus on specific New Chemical Entities (NCEs). JBR-102 is noted for potential activity against both proliferating and non-proliferating cancer cells. JBR-201 is explored as a broad-spectrum antiviral candidate.

Opportunities

JBR-102 addresses the high unmet need in glioblastoma, a devastating cancer with poor survival rates, representing a significant market opportunity.
If its broad-spectrum claim holds, JBR-201 could target multiple large viral disease markets, including seasonal respiratory infections and latent viruses like EBV and HPV.

Risk Factors

Both lead programs are in preclinical stages with high risk of failure; no clinical data exists.
The company is private and pre-revenue, with undisclosed funding, creating financial sustainability risk.
The broad expansion plans for both candidates are ambitious and face intense scientific and competitive challenges.

Competitive Landscape

The GBM space is fiercely competitive with numerous clinical-stage candidates targeting various pathways. The broad-spectrum antiviral field is challenging, with success historically limited to specific virus families; JBR-201 would compete against both approved antivirals and vaccines across its target indications.

More companies in Oncology (General) →More companies in United States →